Hyppää sisältöön
    • Suomeksi
    • In English
Trepo
  • Suomeksi
  • In English
  • Kirjaudu
Näytä viite 
  •   Etusivu
  • Trepo
  • TUNICRIS-julkaisut
  • Näytä viite
  •   Etusivu
  • Trepo
  • TUNICRIS-julkaisut
  • Näytä viite
JavaScript is disabled for your browser. Some features of this site may not work without it.

Epidemiology, clinical characteristics, flares and mortality of generalized pustular psoriasis: a nationwide register study in Finland

Koivusalo, Mirkka; Teitsma, Xavier; Mehtälä, Juha; Vesikansa, Aino; Capion, Susanne Clemen; Airaksinen, Laura; Grönman, Maria; Pasternack, Rafael; Nuutinen, Pauliina; Huilaja, Laura (2025)

 
Avaa tiedosto
Epidemiology_clinical_characteristics_flares_and_mortality_of_generalized_pustular_psoriasis.pdf (1.502Mt)
Lataukset: 



Koivusalo, Mirkka
Teitsma, Xavier
Mehtälä, Juha
Vesikansa, Aino
Capion, Susanne Clemen
Airaksinen, Laura
Grönman, Maria
Pasternack, Rafael
Nuutinen, Pauliina
Huilaja, Laura
2025

Skin health and disease
doi:10.1093/skinhd/vzaf076
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:tuni-2025121811904

Kuvaus

Peer reviewed
Tiivistelmä
Background Generalized pustular psoriasis (GPP) is a chronic and potentially life-threatening inflammatory disease characterized by recurrent, sudden flares often accompanied by systemic symptoms. With the introduction of new, targeted therapies for GPP there is an increased need to better understand patient characteristics to improve disease management. Objectives To assess the epidemiology of GPP, and compare clinical characteristics, treatments and overall survival between GPP and population-based controls and control participants with psoriasis vulgaris. Furthermore, flare occurrence and risk factors for flares were also assessed. Methods All Finnish patients with ≥1 GPP diagnosis (International Classification of Diseases, Tenth Revision: L40.1) in secondary healthcare between 1996 and 2021 and age- and sex-matched control groups were identified. Data on diagnoses, medications and deaths were collected from national registers. Incidence and prevalence were assessed using different case criteria. The primary analysis group included patients with ≥2 GPP diagnoses at a dermatology clinic in specialty care. Results GPP period prevalence decreased from 9.9 to 4.7 and the incidence rate from 4.2 to 2.1 per 100 000 when using stricter case criteria. Psoriasis (73%) and hypertension (49%) were the most common comorbidities among patients with GPP, and topical corticosteroids were the most used medication (92%; P < 0.05 vs. control groups). Overall survival was lower in GPP compared with both control groups (P < 0.001). In total, 43% of the patients experienced a flare during follow-up, of which one-third (33%) had a flare at the time of first GPP diagnosis. Systemic corticosteroid use [hazard ratio (HR) 1.41; 95% confidence interval (CI) 1.10–1.81; P = 0.007] was associated with a higher risk of GPP flares and flares were associated with an increased risk of death (HR 1.7; 95% CI 1.08–2.60; P < 0.05). Conclusions The epidemiology of GPP in Finland was found to be comparable to previously published estimates and associated with a high disease burden and shorter overall survival. Flares occurred frequently during follow-up and are associated with an increased risk of death. Standardized guidelines are crucial to improve the timely diagnosis and management of the disease.
Kokoelmat
  • TUNICRIS-julkaisut [24216]
Kalevantie 5
PL 617
33014 Tampereen yliopisto
oa[@]tuni.fi | Tietosuoja | Saavutettavuusseloste
 

 

Selaa kokoelmaa

TekijätNimekkeetTiedekunta (2019 -)Tiedekunta (- 2018)Tutkinto-ohjelmat ja opintosuunnatAvainsanatJulkaisuajatKokoelmat

Omat tiedot

Kirjaudu sisäänRekisteröidy
Kalevantie 5
PL 617
33014 Tampereen yliopisto
oa[@]tuni.fi | Tietosuoja | Saavutettavuusseloste